Publication
Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (6)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 6
- cancerGastric Carcinomacivic_curation1.00
- cancerMalignant Neoplasmcivic_curation1.00
- drugAlpelisibcivic_curation1.00
- genePIK3CAcivic_curation1.00
- variantPIK3CA Amplificationcivic_curation1.00
- variantPIK3CA Mutationcivic_curation1.00
Curated evidence
Evidence citing this paper (2)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 24608574
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| PIK3CA Amplification1 | ||||||||
| Alpelisib | Gastric CarcinomaALIAS | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID1403474 cancer cell lines from the cancer cell line encyclopedia were assessed for response to the PI3Kalpha inhibitor BYL719 (Alpelisib). PIK3CA amplification was significanly associated with BYL719 resp… (full text at CIViC) PMID 24608574 · Fritsch et al., 2014 · Open in CIViC | civic |
| PIK3CA Mutation1 | ||||||||
| Alpelisib | Malignant NeoplasmALIAS | Predictive | D | Supports Sensitivity Response | 4 | accepted | EID1402A set of 474 cell lines from the Cancer Cell Line Encyclopedia was tested for responsiveness to the PI3Kalpha specific inhibitor BYL719 (Alpelisib). In the PIK3CA wild type subroup of cell lines, 22% … (full text at CIViC) PMID 24608574 · Fritsch et al., 2014 · Open in CIViC | civic |